Contractile effect of endothelin in human placental veins: role of endothelium prostaglandins and thromboxane

Am J Obstet Gynecol. 1993 Oct;169(4):919-24. doi: 10.1016/0002-9378(93)90027-g.

Abstract

Objective: The aim was to study the effects of endothelin-1 on human placental veins and the role of cyclooxygenase products as mediators of these effects.

Study design: Rings of placental veins with and without endothelium were suspended in organ chambers filled with physiologic salt solution. After a period of stabilization at optimal basal tension, isometric tensions in the control group were recorded at increasing concentrations of endothelin-1 (10(-10) to 10(-7) mol/L). Rings in the experimental groups were treated with either indomethacin (cyclooxygenase inhibitor, 10(-5) mol/L), dazoxiben (thromboxane synthetase inhibitor, 10(-4) mol/L), or SQ29548 (thromboxane receptor antagonist, 10(-6) mol/L) before addition of endothelin-1. To demonstrate the presence of functional thromboxane receptors in the rings, contractile responses to U-46619 (10(-9) to 10(-6) mol/L), a thromboxane A2 analog were measured. The effectiveness of SQ29548 blockade was tested in rings treated with SQ29548 (10(-6) mol/L) before addition of U-46619. The concentration-response curves of the treated and control groups were compared with the Student paired t test.

Results: Endothelin-1 in doses of 10(-10) to 10(-7) mol/L caused concentration-dependent contraction of placental veins. Indomethacin significantly reduced the response of veins with endothelium to low endothelin-1 concentrations (10(-9.5) to 10(-9) mol/L), (p < 0.05). However, it had no effect at higher endothelin-1 concentrations or in vessels without endothelium. The presence of functional thromboxane A2 receptors was confirmed by the vasoconstrictor effect of U-46619 and its blockade by treatment with SQ29548. Neither SQ29548 nor the thromboxane A2 synthesis inhibitor dazoxiben significantly influenced the response to endothelin-1.

Conclusions: These results demonstrated that endothelin-1 is a potent vasoconstrictor in the human placental vein. Although functional thromboxane A2 receptors exist in this vessel, endothelin-1's action is independent of thromboxane A2. Prostaglandins may mediate part of the endothelin-1-induced placental vasoconstriction. However, endothelin-1 acts primarily by a direct effect on vascular smooth muscle cells.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
  • Adult
  • Bridged Bicyclo Compounds, Heterocyclic
  • Endothelins / pharmacology*
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / physiology*
  • Fatty Acids, Unsaturated
  • Female
  • Humans
  • Hydrazines / pharmacology
  • Imidazoles / pharmacology
  • In Vitro Techniques
  • Indomethacin / pharmacology
  • Placenta / blood supply*
  • Pregnancy
  • Prostaglandin Endoperoxides, Synthetic / pharmacology
  • Prostaglandin-Endoperoxide Synthases / physiology
  • Prostaglandins / pharmacology*
  • Thromboxane A2 / antagonists & inhibitors
  • Thromboxane A2 / physiology*
  • Thromboxane-A Synthase / antagonists & inhibitors
  • Vasoconstriction / drug effects*
  • Vasoconstrictor Agents / pharmacology
  • Veins

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Endothelins
  • Fatty Acids, Unsaturated
  • Hydrazines
  • Imidazoles
  • Prostaglandin Endoperoxides, Synthetic
  • Prostaglandins
  • Vasoconstrictor Agents
  • dazoxiben
  • Thromboxane A2
  • 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
  • SQ 29548
  • Prostaglandin-Endoperoxide Synthases
  • Thromboxane-A Synthase
  • Indomethacin